NEW YORK, NY / ACCESSWIRE / March 23, 2017 / NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company that delivers a new generation of social communication solutions for business, today announces the online availability of its interview with India Globalization Capital, Inc. (NYSE MKT: IGC), a specialty pharmaceutical company focused on using cannabis and cannabinoids in innovative combination therapy.
The interview can be heard at http://nnw.fm/igc-interview-march-2017
In the interview, India Globalization Capital CEO Ram Mukunda discusses his company's operations and targeted market, as well as leading formulations it is currently working on. "This is a very exciting time for us, an exciting opportunity. We believe that we have first-mover advantage in combination therapy, as very few companies are actually working on cannabis-based pharmaceuticals and within that space we believe that we are the only ones working on combination therapy," Mukunda says in the interview.
What the company does is basically use cannabis and cannabinoids and combine them with other existing drugs to create combination therapies for various diseases. One of the main medical problems IGC is targeting is pain management, which is a massive market that generates national healthcare costs ranging between $460 billion and $635 billion. Another market closely related to pain that the company is also targeting is that of abuse of prescription opioids, which generates approximately $25 billion in healthcare costs, Mukunda explains.
The company's patent filing, IGC-501, is a cannabis-based formulation that focuses on neuropathic and arthritic pain in joints and muscles, with a variety of delivery techniques, Mukunda says. With the completion of its patent filing phase both nationally and internationally, including in Europe and Canada, IGC is planning to now start clinical trials in view of getting the product commercialized as a sustainable alternative to long-term addictive opioid therapies.
In addition to pain management, the company is also working on developing combination therapies for cancer anorexia-cachexia syndrome, a wasting disease responsible for approximately 20 percent of all cancer deaths, currently affecting about 1.3 million people in the U.S. Another condition targeted is medically refractory epilepsy, which affects approximately 50 million people. IGC has patent filings in combination therapy for both these diseases.
Mukunda also speaks about his own background and his company's management team. With a strong background working with public companies and with degrees in electrical engineering and mathematics, Mukunda started the first international pure play long distance carrier that targeted the international community living in metropolitan areas. After taking that company public on NASDAQ, he founded IGC, a company that went through several stages and industries, including mining and construction, before settling in the cannabinoid pharmaceuticals market. IGC's strong management team includes Dr. Ranga Krishna, a certified neurologist with a subspecialty in epilepsy surgery, also serving as director of neurology at the New York Community Hospital, as well as Georgetown University Professor Jack Lynch, who handles the company's intellectual property work and is very focused on building a very strong patent portfolio. Additionally, IGC has a strong research team consisting of people with very solid science backgrounds, with PhDs in biology, chemistry and organic chemistry, who are always looking for how the company can position itself in the combination therapy market.
As for the company's plans for 2017, Mukunda says the main goal is to launch the clinical trials for its pain medication, as well as for its seizure and cachexia formulations. "In addition, we're expecting to file patents in several other areas that we're working in, for instance in PTSD, Alzheimer's, Parkinson's and depression - these are the other four areas that we are very interested in," the IGC CEO concludes.
India Globalization Capital is engaged in the development of cannabis-based therapies to treat pain, PTSD, seizures, cachexia, chronic and terminal neurological and oncological diagnoses, and other life altering conditions. In support of this mission, IGC has assembled a portfolio of patent filings for its phytocannabinoid-based treatments. The company is based in Bethesda, Maryland.
For more information, visit www.igcinc.us.
Follow us at Twitter @IGCIR and Facebook.com/IGCIR/
NetworkNewsWire (NNW) is a multifaceted financial news and publishing company that delivers a new generation of social communication solutions, news aggregation and syndication, and enhanced news release services. Leveraging a professional team of journalists and contributing writers, NNW introduces private and public companies to a wide audience of investors, consumers, journalists and the general public via social media and a rapidly expanding network of over 5,000 key distribution outlets. Cutting through information overload, NNW's innovative and proprietary systems clearly and succinctly deliver its clients much needed visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, visit https://www.NetworkNewsWire.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://nnw.fm/Disclaimer
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.
SOURCE: India Globalization Capital, Inc.